CureVac Scores $296M In GlaxoSmithKline Partnership
GlaxoSmithKline will make a £234 million ($296 million) cash and equity investment in biotechnology company CureVac as they collaborate on up to five vaccines and antibodies targeting infectious diseases, the companies...To view the full article, register now.
Already a subscriber? Click here to view full article